skip navigation links
National Cancer Institute National Cancer Institute U.S. National Institutes of Health
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 14.12e (Release date: 2014-12-29-08:00)
SearchBox Top
SearchBox Bottom
LMP-2:340-349 Peptide Vaccine (Code C62767)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: LMP-2:340-349 Peptide Vaccine

Definition: A peptide vaccine containing amino acids residues from 340 through 349 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin's disease. Vaccination with the LMP-2:340-349 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation.

Label: LMP-2:340-349 Peptide Vaccine

NCI Thesaurus Code: C62767 (Search for linked caDSR metadata)

Synonyms & Abbreviations: (see Synonym Details)
LMP-2:340-349 Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 504594 (check for NCI PDQ closed clinical trial info)
PDQ Open Trial Search ID 504594 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831952

Other Properties:
code C62767
Legacy_Concept_Name LMP-2_340-349_Peptide_Vaccine
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom